RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern
Shihao Zhou, Ruyan Zhang, Haiwei Zhang, Yanling Liu, Yu Wen, Jian Wang, Yuting Li, Zi-Wei You, Xuguang Yin, Hong Qiu, Rui Gong, Guang‐Fu Yang, Jun Guo
Abstract
-RBD immunized group efficiently inhibited the binding of the RBD to ACE2 and protected cells from SARS-CoV-2 and four variants of concern (alpha, beta, gamma and delta), indicating that this adjuvant strategy could be one of the effective means for protein vaccine development.
Topics & Concepts
AdjuvantConjugateAgonistVirologyReceptorAntibodyCoronavirusChemistryBiologyCoronavirus disease 2019 (COVID-19)PharmacologyMedicineImmunologyBiochemistryDiseaseInternal medicineInfectious disease (medical specialty)MathematicsMathematical analysisSARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research StudiesImmune Response and Inflammation